Omeros Corporation (OMER)
NASDAQ
Closed
Aug 27, 2026
Day's Range
18.0052 wk Range
3.94Overview - OMER - Omeros Corporation
Key Statistics
Valuation
Enterprise Value
1.56B
P/E (Trailing)
‪11.68‬
P/E (Forward)
‪16.83‬
PEG Ratio
‪-0.04‬
Price / Sales (TTM)
‪36.32‬
Price / Book
‪-21.85‬
EV / EBITDA
‪-21.70‬
Profitability
Gross Margin
‪94.06%‬
Profit Margin
‪324.88%‬
Operating Margin
‪0.25%‬
Return on Assets
‪-18.67%‬
Return on Equity
‪2.76%‬
Ownership
Shares Outstanding
71.99M
Float
69.28M
Short % of Shares Outstanding
‪22.09%‬
Held by Insiders
‪4.08%‬
Held by Institutions
‪50.58%‬
Price stats
Beta
‪2.53‬
50-Day Avg
‪11.90‬
200-Day Avg
‪11.61‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - OMER - Omeros Corporation
Peers - OMER - Omeros Corporation
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- OMERNASDAQOmeros Corporation1.39BMarket Cap+77.43%52-week change11.64P/E (Trailing)‪324.88%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.11BMarket Cap+32.39%52-week change39.65P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.98BMarket Cap-89.26%52-week change41.64P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE28.27BMarket Cap+9.40%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.41BMarket Cap+22.36%52-week change19.30P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.51BMarket Cap+33.77%52-week change-20.99P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.70BMarket Cap+12.09%52-week change174.00P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - OMER - Omeros Corporation
About
Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. It targets large-market opportunities as well as orphan indications, particularly in areas such as inflammation, coagulopathies, disorders of the central…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
